HRP20041157B1 - Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof - Google Patents

Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

Info

Publication number
HRP20041157B1
HRP20041157B1 HRP20041157A HRP20041157B1 HR P20041157 B1 HRP20041157 B1 HR P20041157B1 HR P20041157 A HRP20041157 A HR P20041157A HR P20041157 B1 HRP20041157 B1 HR P20041157B1
Authority
HR
Croatia
Prior art keywords
preparation
therapeutic use
piperazinylacylpiperidine
derivatives
piperazinylacylpiperidine derivatives
Prior art date
Application number
Other languages
English (en)
Inventor
Francoise Bono
Michael Bosch
Voctor Dos Santos
Jean-Marc Herbert
Dino Nisato
Bernard Tonnerre
Jean Wagnon
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of HRP20041157A2 publication Critical patent/HRP20041157A2/xx
Publication of HRP20041157B1 publication Critical patent/HRP20041157B1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HR20041157 2002-06-07 2003-06-05 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof HRP20041157B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0207001 2002-06-07
PCT/FR2003/001685 WO2003104225A1 (fr) 2002-06-07 2003-06-05 Derives de piperazinylacylpiperidine, leur preparation et leur application en therapeutique

Publications (2)

Publication Number Publication Date
HRP20041157A2 HRP20041157A2 (en) 2005-06-30
HRP20041157B1 true HRP20041157B1 (en) 2012-11-30

Family

ID=29724874

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20041157 HRP20041157B1 (en) 2002-06-07 2003-06-05 Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof

Country Status (29)

Country Link
US (2) US7294628B2 (enExample)
EP (2) EP1513836B1 (enExample)
JP (2) JP4441401B2 (enExample)
KR (1) KR100970812B1 (enExample)
CN (1) CN100448875C (enExample)
AR (2) AR040246A1 (enExample)
AT (2) ATE336491T1 (enExample)
AU (2) AU2003255644B2 (enExample)
BR (1) BR0311828A (enExample)
CA (1) CA2487840C (enExample)
CY (2) CY1107330T1 (enExample)
DE (2) DE60305037T2 (enExample)
DK (2) DK1513835T3 (enExample)
EA (1) EA007501B1 (enExample)
ES (2) ES2264001T3 (enExample)
HR (1) HRP20041157B1 (enExample)
IS (1) IS2302B (enExample)
MA (1) MA27233A1 (enExample)
ME (1) MEP11508A (enExample)
MX (1) MXPA04012341A (enExample)
NO (1) NO329669B1 (enExample)
NZ (1) NZ537044A (enExample)
PL (1) PL208711B1 (enExample)
PT (2) PT1513836E (enExample)
RS (2) RS52588B (enExample)
TW (2) TWI283671B (enExample)
UA (1) UA77526C2 (enExample)
WO (2) WO2003104225A1 (enExample)
ZA (1) ZA200409823B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2862968B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de 4-[(arylmethyl)aminomethyl]piperidine, leur preparation et leur application en therapeutique
FR2862967B1 (fr) * 2003-12-01 2006-08-04 Sanofi Synthelabo Derives de (4-phenylpiperazin-1-yl)acylpiperidine, leur preparation et leur application en therapeutique
JP2007519639A (ja) * 2004-01-08 2007-07-19 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト 複素環アリル誘導体
CA2572821A1 (en) * 2004-07-16 2006-01-26 Janssen Pharmaceutica N.V. Dimeric compounds of piperidine, piperazine or morpholine or their 7-membered analogs suitable for the treatment of neurodegenerative disorders
EP2289510A1 (en) * 2004-09-20 2011-03-02 Xenon Pharmaceuticals Inc. Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
EP1871420A4 (en) * 2005-04-15 2010-09-22 Univ North Carolina PROCESS FOR ENABLING CELL SURVIVAL VIA NEUROTROPHINE MIMETICS
KR20100049500A (ko) * 2007-03-15 2010-05-12 쉐링 코포레이션 글루칸 신타제 억제제로서 유용한 피리다지논 유도체
BRPI0811844A2 (pt) * 2007-05-21 2014-11-18 Reviva Pharmaceuticals Inc Composto, e, método para tratar um paciente
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
FR2932482B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Nouveaux derives de (phenyl-3,6-dihydro-2h-pyridinyl)- (piperazinyl ponte)-1-alcanone et leur utilisation comme inhibiteurs de p75
FR2932481B1 (fr) * 2008-06-13 2010-10-08 Sanofi Aventis Derives de 4-{2-°4-phenyl-3,6-dihydro-2h-pyridin-1-yl!-2- oxo-alkyl}-1-piperazin-2-one, leur preparation et leur application en therapeutique.
JP5863663B2 (ja) 2009-11-12 2016-02-16 ファーマトロフィックス， インコーポレイテッド ニューロトロフィン模倣化合物およびこれらの塩の結晶形態
US10273219B2 (en) 2009-11-12 2019-04-30 Pharmatrophix, Inc. Crystalline forms of neurotrophin mimetic compounds and their salts
FR2953839A1 (fr) * 2009-12-14 2011-06-17 Sanofi Aventis Nouveaux derives d'(heterocycle-piperidine condensee)-(piperazinyl)-1alcanone ou d'(heterocycle-pyrrolidine condensee)-(piperazinyl)-1alcanone et leur utilisation comme inhibiteurs de p75
BR112012014164A2 (pt) 2009-12-14 2016-05-17 Merck Patent Gmbh inibidores da esfingosina quinase
FR2953836B1 (fr) * 2009-12-14 2012-03-16 Sanofi Aventis Nouveaux derives (heterocycle-tetrahydro-pyridine)-(piperazinyl)-1-alcanone et (heterocycle-dihydro-pyrrolidine)-(piperazinyl)-1-alcanone et leur utilisation comme inhibiteurs de p75
EP2606894A1 (en) 2011-12-20 2013-06-26 Sanofi Novel therapeutic use of p75 receptor antagonists
CA3075727A1 (en) * 2017-09-18 2019-03-21 Goldfinch Bio, Inc. Pyridazinones and methods of use thereof
PL3852533T3 (pl) 2018-09-18 2024-09-16 Gfb (Abc), Llc Pirydazynony i sposoby ich zastosowania
EP3858439A1 (en) * 2020-02-03 2021-08-04 Esteve Pharmaceuticals, S.A. Amide derivatives having multimodal activity against pain

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4994455A (en) * 1987-10-26 1991-02-19 Pfizer Inc. Anti-anxiety agents
FR2747041B1 (fr) * 1996-04-05 1998-05-22 Cird Galderma Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies
US6468990B1 (en) * 1999-05-17 2002-10-22 Queen's University At Kingston Method of inhibiting binding of nerve growth factor to p75 NTR receptor
FR2803593B1 (fr) 2000-01-06 2002-02-15 Sanofi Synthelabo Nouvelles tetrahydropyridines, procede pour leur preparation et compositions pharmaceutiques les contenant

Also Published As

Publication number Publication date
MA27233A1 (fr) 2005-02-01
WO2003104225A1 (fr) 2003-12-18
JP4437075B2 (ja) 2010-03-24
DE60307632T2 (de) 2007-08-09
EP1513836A1 (fr) 2005-03-16
DE60307632D1 (de) 2006-09-28
DE60305037T2 (de) 2006-12-14
EP1513835A1 (fr) 2005-03-16
AU2003255645A1 (en) 2003-12-22
NO20045331L (no) 2005-03-07
RS20050014A (sr) 2007-06-04
TWI283671B (en) 2007-07-11
EA007501B1 (ru) 2006-10-27
IS7579A (is) 2004-12-02
UA77526C2 (en) 2006-12-15
HRP20041157A2 (en) 2005-06-30
AU2003255644B2 (en) 2009-02-05
EP1513835B1 (fr) 2006-08-16
NZ537044A (en) 2006-08-31
JP4441401B2 (ja) 2010-03-31
HK1076110A1 (zh) 2006-01-06
ES2264001T3 (es) 2006-12-16
CA2487840A1 (en) 2003-12-18
TW200400185A (en) 2004-01-01
KR20050008802A (ko) 2005-01-21
ES2271637T3 (es) 2007-04-16
JP2005533051A (ja) 2005-11-04
US7468368B2 (en) 2008-12-23
RS52588B (sr) 2013-04-30
AR040246A1 (es) 2005-03-23
JP2005534661A (ja) 2005-11-17
TW200407321A (en) 2004-05-16
CA2487840C (en) 2011-05-17
IS2302B (is) 2007-10-15
AU2003255644A1 (en) 2003-12-22
PT1513835E (pt) 2006-12-29
CY1107330T1 (el) 2012-11-21
DK1513836T3 (da) 2006-09-11
AR040247A1 (es) 2005-03-23
ATE325122T1 (de) 2006-06-15
PL208711B1 (pl) 2011-05-31
CN100448875C (zh) 2009-01-07
US20050176722A1 (en) 2005-08-11
DE60305037D1 (de) 2006-06-08
MEP11508A (en) 2010-06-10
BR0311828A (pt) 2005-03-29
KR100970812B1 (ko) 2010-07-16
DK1513835T3 (da) 2006-12-27
NO329669B1 (no) 2010-11-29
US20060167007A1 (en) 2006-07-27
EA200401470A1 (ru) 2005-06-30
MXPA04012341A (es) 2005-09-30
TWI319400B (en) 2010-01-11
PL374729A1 (en) 2005-10-31
ATE336491T1 (de) 2006-09-15
PT1513836E (pt) 2006-09-29
ZA200409823B (en) 2006-07-26
WO2003104226A1 (fr) 2003-12-18
CN1675203A (zh) 2005-09-28
US7294628B2 (en) 2007-11-13
EP1513836B1 (fr) 2006-05-03
CY1105784T1 (el) 2011-02-02

Similar Documents

Publication Publication Date Title
HUP0401461A3 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
AU2002340999A1 (en) Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
IL180284A0 (en) 2-carbamide-4-phenylthiazole derivatives, preparation thereof and therapeutic use thereof
HRP20041157A2 (en) Piperazinylacylpiperidine derivatives, their preparation and therapeutic use thereof
IL180770A0 (en) Oxopiperidine derivatives, preparation and therapeutic use thereof
IL178402A0 (en) 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof
IL172733A0 (en) Diphenylpyridine derivatives, preparation and therapeutic application thereof
TWI318974B (en) Acylaminothiazole derivatives, their preparation and their therapeutic use
PT1525193E (pt) Derivados do acilaminotiazole e sua utilização como inibidores de beta amilóide
IL180797A0 (en) Amino-tropane derivatives, preparation thereof and therapeutic use thereof
ZA200703876B (en) 2-amido -4-phenylthiazole derivatives, the preparation and therapeutic use thereof
IL166821A0 (en) Novel 1,4-diazabicycloalkane derivatives their preparation and use
PL376790A1 (pl) Pochodne 3-fenylopirydoindolonu, sposób ich wytwarzania i ich zastosowanie terapeutyczne
TWI320413B (en) 1,4-diazabicyclo [ 3.2.2 ] nonanecarboxamide derivatives, preparation thereof and therapeutic use thereof
IL156647A0 (en) 2-arylimino-2,3-dihydrothiazole derivatives, methods for preparing them and therapeutic use thereof
PL375309A1 (en) Acyloxypyrrolidine derivatives, preparation and therapeutic use thereof
PL374858A1 (en) Novel arylimidazole derivatives, preparation and therapeutic uses thereof
PL365342A1 (en) Mikanolide derivatives, their preparation and therapeutic uses
IL161859A0 (en) 3-Heteroaryl-3.5-dihydro-4-oxo-4H-pyridazinoÄ4.5-BÜindole-1-carboxamide derivatives, their preparation and therapeutic use
SI1513836T1 (sl) Derivati piperazinilacilpiperidina, njihova priprava in njihova terapevtska uporaba
SI1513835T1 (sl) Derivati piperazunilacilpiperidina, njihova priprava in njihova terapevtska uporaba
SI1525198T1 (sl) Derivati aciloksi pirolidina in njihova uporaba kot ligandi receptorjev V1b ali V1b in V1a od AVP
SI1525193T1 (sl) Acilaminotiazolni derivati in njihova uporaba kotinhibitorji beta-amiloida
IL180484A0 (en) 4-arylmorpholin-3-one derivatives, preparation and therapeutic use thereof
IL165420A0 (en) Piperazinylacylpiperidine derivatives their preparation and therapeutic use thereof

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
B1PR Patent granted
ODRP Renewal fee for the maintenance of a patent

Payment date: 20130506

Year of fee payment: 11

PBON Lapse due to non-payment of renewal fee

Effective date: 20140605